7:06 AM ET
10-Q
Financial Results
PepGen Q3 2026 Results: Net Loss of $19.4M, Loss Widens
PepGen Inc. is a clinical-stage biotechnology company focused on developing PGN-EDODM1, its lead product candidate. The company remains pre-revenue, reporting significant accumulated losses and a continued need for substantial additional funding to support its research and development programs.
- Key figure
- Net loss $19.4M